載入...
Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
T cell acute lymphoblastic leukemia (T-ALL) is caused by clonal expansion of variant T cell progenitors and is considered as a high risk leukemia. Contemporary single chemotherapy has a limited effect due to dynamic and versatile properties of T-ALL. Here IRAK1/4 inhibitor and ABT-737 were co-encaps...
Na minha lista:
| 發表在: | Int J Nanomedicine |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5673049/ https://ncbi.nlm.nih.gov/pubmed/29184402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S146875 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|